International Journal of Clinical Science and Medical Research

Background: Acute exacerbations of Bronchial Asthma and Chronic Obstructive Pulmonary Disease (COPD) are common causes of hospital admission and respiratory distress. Nebulized Magnesium Sulfate has bronchodilatory and anti-inflammatory effects and may improve early clinical recovery when used as an adjunct therapy.

Methods: This prospective comparative cross-sectional observational study was conducted in the Department of Medicine at Monno Medical College & Hospital, Manikganj, Bangladesh from October 2025 to March 2026. A total of 200 patients with acute exacerbations were enrolled, including 100 asthma and 100 COPD patients. Baseline demographic and clinical parameters were recorded and early clinical recovery within 24 hours after nebulized magnesium sulfate therapy was evaluated. Outcomes included improvement in respiratory parameters, requirement of ICU admission, mechanical ventilation and duration of hospital stay.

Results: Among asthma patients (n = 100), the majority were aged 18–30 years (28%), whereas most COPD patients were in the >60 years age group (32%), showing a significant age difference between the groups (p < 0.001). Asthma patients were generally younger, while COPD patients were older and more commonly smokers. Improvement in respiratory rate (81% vs 69%), SpO₂ (84% vs 73%) and PEFR >20% (76% vs 63%) was significantly higher in asthma patients (p<0.05). ICU admission was lower in asthma patients (9%) compared to COPD patients (23%) and the mean hospital stay was shorter (3.7±1.5 vs 4.9±2.1 days). Adverse effects were minimal.

Conclusion: Nebulized magnesium sulfate appears to be a safe and effective adjunct therapy that improves early recovery and reduces ICU admission, particularly among asthma patients.

Nebulized magnesium sulfate, acute asthma, COPD exacerbation, bronchodilator therapy, ICU admission.

1. Shivanthan MC, Rajapakse S. Magnesium for acute exacerbation of chronic obstructive pulmonary disease: A systematic review of randomised trials. Annals of thoracic medicine. 2014 Apr 1;9(2):77-80.
2. Bessmertny O, DiGregorio RV, Cohen H, Becker E, Looney D, Golden J, Kohl L, Johnson T. A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults. Annals of emergency medicine. 2002 Jun 1;39(6):585-91.
3. Gershkovich D. Acute exacerbation of asthma (Doctoral dissertation, Sveučilište u Zagrebu, Sveučilište u Zagrebu, Medicinski fakultet). 2023
4. Maselli DJ, Peters JI. Medication regimens for managing acute asthma. Respiratory care. 2018 Jun;63(6):783-96.
5. Albertson TE, Sutter ME, Chan AL. The acute management of asthma. Clinical reviews in allergy & immunology. 2015 Feb;48(1):114-25.
6. Papiris SA, Manali ED, Kolilekas L, Triantafillidou C, Tsangaris I. Acute severe asthma: new approaches to assessment and treatment. Drugs. 2009 Dec;69(17):2363-91.
7. Carriera L, Mari PV, Barone R, Ielo S, Cataldo E, Di Tomasso M, Bezzi M, Smargiassi A, Inchingolo R, Coppola A. Potential novel role of asthma biologics as rescue therapy in the intensive care unit for life-threatening asthma exacerbations: a systematic review. Monaldi Archives for Chest Disease. 2026.
8. Bourdin A, Bjermer L, Brightling C, Brusselle GG, Chanez P, Chung KF, Custovic A, Diamant Z, Diver S, Djukanovic R, Hamerlijnck D. ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. European respiratory journal. 2019 Sep 28;54(3).
9. Albertson TE, Schivo M, Gidwani N, Kenyon NJ, Sutter ME, Chan AL, Louie S. Pharmacotherapy of critical asthma syndrome: current and emerging therapies. Clinical reviews in allergy & immunology. 2015 Feb;48(1):7-30.
10. Roy SR, Milgrom H. Management of the acute exacerbation of asthma. Journal of Asthma. 2003 Jan 1;40(6):593-604.
11. Lin J, Xing B, Chen P, Huang M, Zhou X, Wu C, Yang D, Yin K, Cai S, Cheng X, Hao C. Chinese expert consensus-based guideline on assessment and management of asthma exacerbation. Journal of Thoracic Disease. 2019 Dec;11(12):4918.
12. Conemans L, Demir E, Bischoff M, Franssen F, Simons S. Out of Breath, out of Options: Benralizumab as a Last Hope in ICU‐Treated Near‐Fatal Eosinophilic Asthma: A Case Series. Respirology Case Reports. 2025 Mar;13(3):e70117.
13. Buhl R, Farmer SG. Current and future pharmacologic therapy of exacerbations in chronic obstructive pulmonary disease and asthma. Proceedings of the American Thoracic Society. 2004 Apr;1(2):136-42.
14. Agarwal R, Dhooria S, Aggarwal AN, Maturu VN, Sehgal IS, Muthu V, Prasad KT, Yenge LB, Singh N, Behera D, Jindal SK. Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations. Lung India. 2015 Apr 1;32(Suppl 1):S3-42.
15. Guthrie A. Chronic obstructive pulmonary disease series Part 4: identifying, managing and preventing exacerbations. The Senior Care Pharmacist. 2023 Sep 1;38(9):361-9.
16. Kling S. Severe asthma and acute attacks: diagnosis and management in adults and children: CPD. South African Family Practice. 2007 Jun 1;49(5):36-40.
17. Kinser D. The Patient With Asthma in the Emergency Department. InBronchial Asthma: A Guide for Practical Understanding and Treatment 2006 (pp. 143-162). Totowa, NJ: Humana Press.
18. Kleerup EC. Critical Care for Acute Severe Asthma. InPractical Pulmonary and Critical Care Medicine 2006 Jan 20 (pp. 63-100). CRC Press.
19. Villa-roel C, Rowe BH. Management of acute asthma, COPD and asthma-COPD overlap. InAsthma, COPD and Overlap 2018 Mar 22 (pp. 243-256). CRC Press.
20. Abdelrahim ME, Saeed H, Harb HS, Madney YM. Essentials of Aerosol Therapy in Critically Ill Patients. Springer Nature; 2021 Oct 21.
21. BARNES N, FUIKA SG. 15 Exacerbations of Asthma in Adults. Pharmacology and Therapeutics of Airway Disease. 2009 Oct 27:74.